Non-Receptor-Tyrosine-Protein-Kinase-TYK2-(TYK2-or-EC-2.7.10.2)-Pipeline-Review-H2-2017

Non-Receptor-Tyrosine-Protein-Kinase-TYK2-(TYK2-or-EC-2.7.10.2)-Pipeline-Review-H2-2017


  • Products Id :- GMDHC1003TDB
  • |
  • Pages: 68
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)-Pipeline Review, H2 2017

Summary

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)-Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 9 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Central Nervous System, Dermatology, Musculoskeletal Disorders, Ophthalmology and Undisclosed which include indications Ulcerative Colitis, Psoriasis, Autoimmune Disorders, Inflammation, Inflammatory Bowel Disease, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Alopecia, Anaplastic Large Cell Lymphoma (ALCL), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hypersensitivity, Lupus Erythematosus, Lupus Nephritis, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Systemic Lupus Erythematosus, T-Cell Leukemia, Unspecified, Uveitis and Waldenstrom Macroglobulinemia.

The latest report Non Receptor Tyrosine Protein Kinase TYK2-Pipeline Review, H2 2017, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)-Overview

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)-Companies Involved in Therapeutics Development

Array BioPharma Inc

Bristol-Myers Squibb Company

Nimbus Therapeutics LLC

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Takeda Pharmaceutical Company Ltd

Theravance Biopharma Inc

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)-Drug Profiles

ARRY-624-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986165-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDI-031232-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDI-031301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDI-031407-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OST-122-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06700841-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-20347-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-29-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-33-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TYK2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TYK2 for Ulcerative Colitis and Autoimmune Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-3504-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)-Dormant Products

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)-Discontinued Products

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)-Product Development Milestones

Featured News & Press Releases

Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis

Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL

Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma

Jun 14, 2017: Bristol-Myers Squibb To Present on BMS-986165 at the Annual European Congress of Rheumatology (EULAR 2017)

May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association

May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma

Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization

Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization

Nov 29, 2016: Sareum to Present TYK2 Cancer Research Programme at the 2016 AACR-NCI-EORTC International Conference

Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition

Oct 24, 2016: Sareum Holdings: Successful Outcome from TYK2 Feasibility Study

Oct 04, 2016: Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis

Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor

Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings

Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Array BioPharma Inc, H2 2017

Pipeline by Bristol-Myers Squibb Company, H2 2017

Pipeline by Nimbus Therapeutics LLC, H2 2017

Pipeline by Pfizer Inc, H2 2017

Pipeline by Portola Pharmaceuticals Inc, H2 2017

Pipeline by Sareum Holdings Plc, H2 2017

Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Pipeline by Theravance Biopharma Inc, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Array BioPharma Inc

Bristol-Myers Squibb Company

Nimbus Therapeutics LLC

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Takeda Pharmaceutical Company Ltd

Theravance Biopharma Inc

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Therapeutic Products under Development, Key Players in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Therapeutics, Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Pipeline Overview, Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Pipeline, Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Pipeline Assessment

select a license
Single User License
USD 3500 INR 249830
Site License
USD 7000 INR 499660
Corporate User License
USD 10500 INR 749490

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com